Our study suggested a possible mechanism: in the tumor microenvironment, PD-1+ mast cells are enhanced by PD-1 antibody, releasing more histamine and cytokines to reduce the effect of immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.